Total pharma industry deals for March 2019 worth $9.75bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 70.1% over the previous month and a drop of 64.3% when compared with the last 12-month average of $27.31bn.

In terms of number of deals, the sector saw a drop of 6% over the last 12-month average with 126 deals against the average of 134 deals.

In value terms, North America led the activity with deals worth $4.53bn.

Pharma industry deals in March 2019: Top deals

The top five pharma deals accounted for 63.8% of the overall value during March 2019.

The combined value of the top five pharma deals stood at $6.23bn, against the overall value of $9.75bn recorded for the month. The top announced pharma deal tracked by GlobalData in March 2019 was Grifols‘ $1.93bn acquisition of Shanghai RAAS Blood Products.

In second place was the $1.7bn acquisition of Brammer Bio by Thermo Fisher Scientific and in third place was Fujifilm’s $890m acquisition of Biogen Denmark Manufacturing.

The $877m acquisition of Nightstar Therapeutics by Biogen and Waypoint Group Holdings’ private equity deal with Stallergenes Greer for $830.01m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.